Capsigen

Vancouver, US · 1 known investors

Capsigen engineers customized AAV (adeno-associated virus) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE) screening platform and data science to deliver gene therapies to specific target cells. The company develops fit-for-purpose viral vectors for treating difficult-to-treat diseases, including CNS and neuromuscular disorders.